This site is intended for healthcare professionals

Keytruda demonstrated superior disease-free survival in KEYNOTE 564, compared with placebo as adjuvant therapy in patients with renal cell carcinoma following surgery.

Read time: 1 mins
Last updated:9th Apr 2021
Published:9th Apr 2021
Condition: Renal Cell Carcinoma
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest